245 related articles for article (PubMed ID: 32927513)
1. [Clinicopathological features and prognosis of 59 patients with platelet-derived growth factor α-mutant gastrointestinal stromal tumor].
Sun XF; Gao XD; Yuan W; Sun JY; Fu M; Xue AW; Li H; Shu P; Fang Y; Hou YY; Shen KT; Sun YH; Qin J; Qin XY
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep; 23(9):880-887. PubMed ID: 32927513
[No Abstract] [Full Text] [Related]
2. Clinicopathological and therapeutic analysis of PDGFRA mutated gastrointestinal stromal tumor.
Huang W; Yuan W; Ren L; Liang H; Du X; Sun X; Fang Y; Gao X; Fu M; Sun Y; Shen K; Hou Y
Pathol Res Pract; 2022 Nov; 239():154138. PubMed ID: 36183438
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic Characteristics and Prognosis of PDGFRA-Mutant Gastrointestinal Stromal Tumors: A Large-Scale, Multi-Institutional, Observational Study in China.
Zhang P; Wang M; Li J; Gao X; Zhang B; Liang H; Zhou Y; Liao G; Feng F; Zhou Y; Yu J; Zhang J; Zhou Y; Ye Y; Chen J; Zhao Q; Shen K; Cao H; Tao K
Adv Ther; 2022 Jun; 39(6):2920-2931. PubMed ID: 35462602
[TBL] [Abstract][Full Text] [Related]
4. [Differences in clinicopathological features, gene mutations, and prognosis between primary gastric and intestinal gastrointestinal stromal tumors in 1061 patients].
Li JX; Sun L; Zhao S; Shao B; Guo YH; Chen S; Liang H; Sun Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Apr; 26(4):346-356. PubMed ID: 37072312
[No Abstract] [Full Text] [Related]
5. [Reappraisals of biological behaviors of PDGFRA mutant gastrointestinal stromal tumor].
Yuan W; Huang W; Ren L; Liang HY; Dong SY; Du XY; Xu C; Fang Y; Shen KT; Hou YY
Zhonghua Bing Li Xue Za Zhi; 2024 Jan; 53(1):46-51. PubMed ID: 38178746
[No Abstract] [Full Text] [Related]
6. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.
Cassier PA; Fumagalli E; Rutkowski P; Schöffski P; Van Glabbeke M; Debiec-Rychter M; Emile JF; Duffaud F; Martin-Broto J; Landi B; Adenis A; Bertucci F; Bompas E; Bouché O; Leyvraz S; Judson I; Verweij J; Casali P; Blay JY; Hohenberger P;
Clin Cancer Res; 2012 Aug; 18(16):4458-64. PubMed ID: 22718859
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic relevance of overexpressions of PKC-θ and DOG-1 and KIT/PDGFRA gene mutations in extragastrointestinal stromal tumors: a Korean six-centers study of 28 cases.
Kim KH; Nelson SD; Kim DH; Choi KU; Kim SJ; Min KW; Jang KS; Paik SS; Oh YH; Chae SW; Sohn JH; Kim HJ; Cho YK; Kim BI; Park DI; Sohn CI; Oh S; Choi SH; Choi YJ; Woo HY; Park YL; Park SJ; Lee SH; Ryu S; DO SI; Kang G; Kim K; Cho YH; Pyo JS
Anticancer Res; 2012 Mar; 32(3):923-37. PubMed ID: 22399613
[TBL] [Abstract][Full Text] [Related]
8. Impact of KIT and PDGFRA gene mutations on prognosis of patients with gastrointestinal stromal tumors after complete primary tumor resection.
Hou YY; Grabellus F; Weber F; Zhou Y; Tan YS; Li J; Shen KT; Qin J; Sun YH; Qin XY; Bockhorn M; Gerken G; Broelsch CE; Frilling A
J Gastrointest Surg; 2009 Sep; 13(9):1583-92. PubMed ID: 19291337
[TBL] [Abstract][Full Text] [Related]
9. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST).
Dematteo RP; Gold JS; Saran L; Gönen M; Liau KH; Maki RG; Singer S; Besmer P; Brennan MF; Antonescu CR
Cancer; 2008 Feb; 112(3):608-15. PubMed ID: 18076015
[TBL] [Abstract][Full Text] [Related]
10. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis.
Andersson J; Bümming P; Meis-Kindblom JM; Sihto H; Nupponen N; Joensuu H; Odén A; Gustavsson B; Kindblom LG; Nilsson B
Gastroenterology; 2006 May; 130(6):1573-81. PubMed ID: 16697720
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological and molecular aspects of foregut gastrointestinal stromal tumours.
Chen J; Gundara JS; Haddad R; Schiavone V; Meldrum C; Samra JS; Gill AJ; Hugh TJ
ANZ J Surg; 2014; 84(1-2):52-8. PubMed ID: 23171083
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience.
Wozniak A; Rutkowski P; Piskorz A; Ciwoniuk M; Osuch C; Bylina E; Sygut J; Chosia M; Rys J; Urbanczyk K; Kruszewski W; Sowa P; Siedlecki J; Debiec-Rychter M; Limon J;
Ann Oncol; 2012 Feb; 23(2):353-60. PubMed ID: 21527588
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal stromal tumors presenting as omental masses--a clinicopathologic analysis of 95 cases.
Miettinen M; Sobin LH; Lasota J
Am J Surg Pathol; 2009 Sep; 33(9):1267-75. PubMed ID: 19440146
[TBL] [Abstract][Full Text] [Related]
14. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity.
Weisberg E; Wright RD; Jiang J; Ray A; Moreno D; Manley PW; Fabbro D; Hall-Meyers E; Catley L; Podar K; Kung AL; Griffin JD
Gastroenterology; 2006 Dec; 131(6):1734-42. PubMed ID: 17087936
[TBL] [Abstract][Full Text] [Related]
15. KIT-negative gastrointestinal stromal tumor of the abdominal soft tissue: a clinicopathologic and genetic study of 10 cases.
Yamamoto H; Kojima A; Nagata S; Tomita Y; Takahashi S; Oda Y
Am J Surg Pathol; 2011 Sep; 35(9):1287-95. PubMed ID: 21836495
[TBL] [Abstract][Full Text] [Related]
16. [Status and clinical implication of c-kit and PDGFRA mutations in 165 cases of gastrointestinal stromal tumor (GIST)].
He HY; Fang WG; Zhong HH; Li Y; Zheng J; Du J; Heng WJ; Wu BQ
Zhonghua Bing Li Xue Za Zhi; 2006 May; 35(5):262-6. PubMed ID: 16776995
[TBL] [Abstract][Full Text] [Related]
17. Imatinib efficacy by tumor genotype in Korean patients with advanced gastrointestinal stromal tumors (GIST): The Korean GIST Study Group (KGSG) study.
Kang HJ; Ryu MH; Kim KM; Park YS; Choi J; Ryoo BY; Kim WH; Im SA; Bang YJ; Park SH; Lee JH; Chung IJ; Bae HI; Kim JG; Lee KH; Song HS; Kwon HC; Baek JH; Shin DB; Lee KE; Kang YK
Acta Oncol; 2012 Apr; 51(4):528-36. PubMed ID: 22150077
[TBL] [Abstract][Full Text] [Related]
18. [Status and clinical analysis of c-kit and PDGFRA mutations in the gastrointestinal stromal tumors].
Du CY; Shi YQ; Zhou Y; Fu H; Zhao GF
Zhonghua Wei Chang Wai Ke Za Zhi; 2008 Jul; 11(4):371-5. PubMed ID: 18636362
[TBL] [Abstract][Full Text] [Related]
19. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation.
Dewaele B; Wasag B; Cools J; Sciot R; Prenen H; Vandenberghe P; Wozniak A; Schöffski P; Marynen P; Debiec-Rychter M
Clin Cancer Res; 2008 Sep; 14(18):5749-58. PubMed ID: 18794084
[TBL] [Abstract][Full Text] [Related]
20. The analysis of status and clinical implication of KIT and PDGFRA mutations in gastrointestinal stromal tumor (GIST).
Du CY; Shi YQ; Zhou Y; Fu H; Zhao G
J Surg Oncol; 2008 Sep; 98(3):175-8. PubMed ID: 18618605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
